Drug Trial Radar · NCT04914117
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Nov 29, 2021
Primary completion
Nov 15, 2022
Study completion Mar 11, 2023
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).
Conditions
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Locally Advanced Solid Tumor
Interventions
RC118 for injectionDrug
RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD/MAD based on number of dose-limiting toxicities (DLTs)Time frame: Up to 18 months
- Determine Recommended Phase 2 Dose (RP2D)Time frame: Up to 18 months
- Adverse EventsTime frame: Up to 18 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Remegen Site #12
Macquarie Park, New South Wales, Australia
Remegen Site #14
Bedford Park, South Australia, Australia
Remegen Site #13
Frankston, Victoria, Australia
Remegen Site #11
Malvern, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.